We Are Tarian Pharma : A Clinical-Stage
Oncology Supportive Care Company.
Discover the team and milestones.
A Timeline of
Clinical Progress,
Purpose,
& Protection
Toward Market Launch
Tarian Pharma plans to initiate a Phase 3 clinical trial in 2027, supported by a targeted €15 million fundraising round. This next stage will assess the safety and efficacy of TAR-0520 in oncology supportive care and support the company’s objective of a potential market launch in 2030, subject to successful clinical development and regulatory approval.
Clinical Trials on Cancer Patients Begin
A second funding round of €2 million enabled Tarian to launch Phase 2 clinical studies in cancer patients, evaluating TAR-0520 across priority oncology supportive care indications.
First Funding & Early Validation
Tarian raised a €1.5 million seed round from private investors, received the national i-Lab Innovation Prize, and secured a €375,000 grant plus seed financing from BPI France. These funds supported the preclinical program and Phase 1 studies in healthy volunteers, generating data on skin tolerance and systemic safety.
Tarian Pharma is Born
Founded by three dermatology drug development experts, Tarian Pharma emerged with a mission to help protect cancer patients from severe skin toxicities caused by oncology treatments. The name Tarian, meaning “shield” in Welsh, became our guiding symbol.
Our Team of Dermatology
Drug Development Experts
Tarian Pharma brings together
dermatology, pharmaceutical development, and clinical-stage experience
to advance supportive care in oncology
Dr Philippe ANDRES
Education & Training
25 years of industry experience
MD, Dermatologist
Philippe brings more than 25 years of experience in dermatology and pharmaceutical development, including 17 years at Galderma /Nestlé Skin Health in senior roles spanning medical affairs, early clinical development, scientific communication and global project leadership. His career combines clinical dermatology with extensive experience in the development and positioning of innovative dermatological products.
Contact Information
Dr Janusz CZERNIELEWSKI
Education & Training
35 years of industry experience
MD, PhD, MBA, Dermatologist
Janusz, a dermatologist and executive (MD, MBA), has more than 40 years of experience in skin biology research and dermatological product development, combining his scientific and dermatology expertise with business and commercial strategy in senior international leadership roles at Galderma and Nestlé Skin Health.
During more than three decades at Galderma, he held senior management responsibilities across R&D, including pharmaceutical and preclinical product development, clinical research, global medical affairs, global marketing, and business development. He ultimately served on the Executive Board of Galderma and subsequently on the Executive Board of Nestlé Skin Health.
His expertise spans the full dermatological product development lifecycle, from skin biology, pharmacology, and preclinical and clinical research through regulatory submissions & international product development and management. He has extensive experience working with European regulatory authorities and the FDA and has overseen development programs covering prescription, OTC, and aesthetic dermatology products. He has authored or contributed to more than 100 scientific papers and book chapters.
At Tarian Pharma, he draws on this unique combination of clinical dermatology expertise, scientific knowledge, dermatological product development experience and international leadership to support the company’s medical and scientific strategy.
Contact Information
Dr Gareth WINCKLE
Education & Training
20 years of industry experience
PhD, Pharmacist
Gareth brings more than 20 years of international experience in topical drug development, with senior scientific and leadership roles at Galderma/Nestlé Skin Health, Dow Pharmaceutical Sciences and Nuvisan. Throughout his career, he has led multidisciplinary teams and contributed to the development of topical, transdermal and other drug delivery programs across dermatology and related therapeutic areas.
His expertise spans formulation design, dermal delivery, skin permeation, product optimization, scale-up, GMP manufacturing and clinical development and regulatory support. He has contributed to the development of more than 50 drug compounds and is a co-inventor on more than 60 patents and patent applications in topical and transdermal drug delivery. His work combines scientific innovation with a strong understanding of topical product development, intellectual property and industrial translation.
At Tarian Pharma, Gareth leads the formulation and pharmaceutical development of TAR-0520, working across formulation, manufacturing and analytical to support its progression from scientific concept to clinical-stage product. His role is focused on translating Tarian’s scientific approach into a robust, scalable & protected pharmaceutical product.